Evaluating the Impact of FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients With Muscle Invasive Bladder Cancer

• Status: Not yet recruiting
• Trial end date: 2029-02-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the impact of 18F-FDG-PET-CT on the staging of patients with muscle invasive bladder cancer. Based on the results of 2 18F-FDG-PET-CT's patients are stratified in non-metastatic, oligometastatic and polymetastatic bladder cancer patients and the treatment is adapted accordingly to improve overall survival.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Ghent

Criteria

Inclusion Criteria:

• newly diagnosed MIBC with no signs of metastasis on conventional imaging (i.e. CT)

Exclusion Criteria:

• Extra-pelvic metastasis (M1 disease) on conventional imaging (CT thorax/abdomen/MRI)

• Prior RT enabling MDT

• Contra-indication for 18F FDG PET-CT

• Contraindications to radiotherapy (including active inflammatory bowel disease)

• No prior Cisplatin-based chemotherapy in the neo-adjuvant setting

• Patient refusing 18F FDG PET-CT

• Patient refusing MDT or immunotherapy

• Other primary tumour diagnosed <5 years ago and for which treatment is still required